News
Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...
A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...
Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular ...
In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, ...
1h
India Today on MSNWeight-loss drugs work, but here's when the weight starts to returnNew research reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Experts urge ...
Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...
35mon MSN
The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...
12h
News-Medical.Net on MSNCan one drug do it all? Reviewing the expanding clinical universe of GLP-1 agonistsLandmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...
Clinical trial data review on weight-loss drugs reveals weight regain patterns post-medication discontinuation, impacting weight management strategies.
Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...
12h
News Medical on MSNAnti-obesity medications associated with weight rebound post-treatment,suggests studyPatients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, ...
Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results